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Connexins are homologous four-transmembrane-domain proteins and major components of gap junctions.
We recently identiﬁed mutations in either GJB3 or GJB4 genes, encoding respectively connexin 31 (Cx31) or
30.3 (Cx30.3), as causally involved in erythrokeratodermia variabilis (EKV), a mostly autosomal dominant
disorder of keratinization. Despite slight differences, phenotypes of EKV Mendes Da Costa (Cx31) and EKV
Cram–Mevorah (Cx30.3) show major clinical overlap and both Cx30.3 and Cx31 are expressed in the upper
epidermal layers. These similarities suggested to us that Cx30.3 and Cx31 may interact at a molecular level.
Indeed, expression of wild-type Cx30.3 in HeLa cell resulted only in minor amounts of protein addressed to
the plasma membrane. Mutant Cx30.3 was hardly detectable and disturbed intercellular coupling. In sharp
contrast, co-expression of both wild-type proteins led to a gigantic increase of stabilized heteromeric gap
junctions. Furthermore, co-expressed wild-type Cx30.3 and Cx31 coprecipitate, which demonstrates a
physical interaction. Inhibitor experiments revealed that this interaction begins in the endoplasmic reticulum.
These results not only provide new insights into epidermal connexin synthesis and polymerization, but also
allow a novel molecular explanation for the similarity of EKV phenotypes.
INTRODUCTION
Gap junctions are clusters of intercellular plasma membrane
channels connecting the cytoplasm of neighboring cells and
allowing free transfer of small molecules (less than 1 kDa). Gap
junctions are essential for intercellular communication and
thus for control of cell fate and tissue homeostasis. The
intercellular channels are formed by the docking of two
connexons consisting of six connexins. All the connexins within
a connexon can be the same (homomeric) or different (hetero-
meric) and the two connexons docking together can be identical
(homotypic junctions) or different (heterotypic junctions).
Connexins (Cx) compose a large and highly homologous
gene family encoding plasma membrane proteins. Connexins
contain four transmembrane domains linked by one cytoplas-
mic and two extracellular loops; N and C termini are located on
the cytoplasmic side. Transmembrane domains bear conserved
amino acids, whereas the cytoplasmic loop and the C terminal
region are the most variable parts of connexins. Twenty
connexins with different selectivity properties have been
described (1,2) and each tissue expresses a specific subset (3).
The importance of the physiological functions of connexins is
illustrated by the identification of connexin mutations as the
molecular cause of various human diseases (4), such as X-
linked Charcot–Mary–Tooth peripheral neuropathy, cataract or
hearing loss.
In skin, at least nine different connexins are expressed (5). In the
basal cell layer, Cx26 is the predominant connexin, while in
the spinous and granular cell layers themost expressed connexins
areCx43,Cx31 andCx37 (3,6–8). Cx30.3 is expressed in kidney,
placenta and skin (9). Cx31 andCx30.3 appear to be coexpressed
in the suprabasal compartment of mouse and human
epidermis (8). Cx31 is preferentially expressed in the stratum
corneum and the stratum granulosum (7). The precise localiza-
tion of Cx30.3 has not been reported yet. Different skin diseases
are caused by connexin mutations (3,10). For instance mutations
of Cx26 lead to Vohwinkel syndrome (palmoplantar kerato-
derma and hearing loss) (11) and KID syndrome (erythroker-
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atoderma, deafness and keratitis) (12,13) or mutations of Cx30
are responsible for Clouston syndrome (hearing loss and hidrotic
ectodermal dysplasia) (14). Recently, we have identified
mutations of Cx31 (11,16–20) and Cx30.3 (8,21) to cause
autosomal dominant erythrokeratodermia variabilis (EKV;MIM
133200) characterized by fixed hyperkeratotic plaques and
transient erythematous areas. There is similarity in the clinical
pictures of patients with EKV due to Cx31 and Cx30.3
mutations, despite minor differences, with EKV Cram–
Mevorah (Cx30.3) being more annular in appearance (8,21)
than EKV of the Mendes Da Costa type (Cx31). Furthermore,
Cx30.3 and Cx31 are expressed in the upper differentiating
epidermal layers (6–8). In addition to epidermis, Cx31 is
expressed in the cochlea, and some mutations have been
associated with hearing loss or impairment without obvious
cutaneous phenotypes (10,19,22). The similarities of the clinical
phenotypes of EKV which are due to mutations of Cx30.3 and
Cx31 suggested to us that Cx30.3 and Cx31 might cooperate
structurally or functionally at amolecular level. Therefore, we set
out to analyze the coexpression of Cx31 and Cx30.3 and to study
the influence of the Cx30.3 mutation F137L (F137L-Cx30.3)
(21), which affects a highly conserved amino acid oriented
towards the channel pore formed by the third transmembrane
domain of the protein (23).
RESULTS
Expression in stable cell lines
HeLa cells, which are deficient in connexin expression, were
transfected with plasmids driving the expression of one or more
wild-type (WT) or mutant connexins and stably transfected
cells were selected. RT–PCR was performed to assess the
expression of transgenes in stable cell lines (Fig. 1A). A Cx31
transcript was detected in cells transfected with WT-Cx31, WT-
Cx31/WT-Cx30.3 and WT-Cx31/F137L-Cx30.3. Four cell lines
expressed a transcript for Cx30.3 (WT-Cx31/WT-Cx30.3, WT-
Cx31/F137L-Cx30.3, WT-Cx30.3 and F137L-Cx30.3). The
presence of the mutation F317L in Cx30.3 was checked by
restriction enzyme digestion. Connexin proteins were detected
by western blotting (Fig. 1B and C). The expression pattern of
immunolabeled proteins was fully in agreement with that of the
corresponding transcripts. Interestingly the levels of Cx31 were
markedly decreased when mutant Cx30.3 was coexpressed
(Fig. 1B). No connexins were detected in non-transfected HeLa
cells (Fig. 1A, B and C, lane 6).
Localization of wild-type and mutated connexins
Immunolabeling (Fig. 2A and B) with specific antibodies
revealed that WT-Cx30.3 and WT-Cx31 localized at the plasma
membrane as small plaques at points of contact between
adjacent cells. This membrane localization was confirmed by
colocalization with N-Cadherin (Fig. 2D). Nevertheless,
expression of WT-Cx30.3 alone resulted in a protein with a
localization different to that of WT-Cx31 as judged by a faint
and more diffuse immunostaining (Fig. 2B). When WT-Cx31
and WT-Cx30.3 were coexpressed, the staining was much
stronger and large plaques were seen at areas of cell–cell contact
(Fig. 3A, C and E), where the two connexins were precisely
colocalized in these cells (Fig. 3A, C and E). In contrast,
coexpression of F137L-Cx30.3 and of WT-Cx31 resulted in a
diffuse staining with only a few detectable dots of WT-Cx31
at the cell membrane (Fig. 3B, D and F). Consequently,
we supposed that there was a cooperation between both
connexin which enhanced the formation of gap junction and
that the F137L mutation of Cx30.3 had a dominant negative
effect.
When cells expressing WT-Cx31 were co-cultured with cells
expressing WT-Cx30.3, the staining was similar to that of the
cells cultured separately (data not shown), indicating that
collaboration of the two proteins occurs during the formation of
heteromeric connexons and not in the heterotypic docking of
two connexons of adjacent cells, and that this heteromerization
is essential for the trafficking of Cx30.3.
Figure 1. Expression of connexins in the stable cell lines. (A) RT–PCR ampli-
fication of RNA from HeLa cells expressing WT-Cx31 (lane 1), WT-Cx31
and WT-Cx30.3 (lane 2), WT-Cx31 and F137L-Cx30.3 (lane 3), WT-Cx30.3
(lane 4), F137L-Cx30.3 (lane 5) and normal HeLa cells (lane 6) using
primers specific for either Cx31 or Cx30.3. Western blot analysis of the same
stable cell lines with anti-V5 antibody for Cx31 (B) and anti-myc antibody
for Cx30.3 (C). The numbers above each lane correspond to those mentioned
in (A).
Figure 2. Plasma membrane localization of WT-Cx31 and WT-Cx30.3 in stable
HeLa cell lines. (A) Immunofluorescence on cells expressing WT-Cx31 (A),
WT-Cx30.3 (B), F137L-Cx30.3 (C) and WT-Cx31/WT-Cx30.3 (D) with
anti-V5 antibody (A, in red), anti-myc antibody (B, C and D, in green) and
N-Cadherin antibody (D in red).
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Integration of connexins into gap junctions
Incorporation of connexins into gap junction plaques correlates
with a loss of solubility in Triton X-100 (24–27). Protein
extracts from different HeLa cells were thus separated into
soluble and insoluble fractions. Connexins in soluble fractions,
corresponding to dispersed connexons, were observed at
similar levels in HeLa cells whether WT-Cx30.3 or F137L-
Cx30.3 was coexpressed with WT-Cx31. Connexins in the
TritonX-100 insoluble fraction were also detected in both cell
lines. However, the abundance of connexins in this fraction was
markedly decreased in cells expressing the mutant connexin, as
judged by immunolabeling of Cx31 (Fig. 3G), indicating that
less gap junctions are formed in the presence of F137L-Cx30.3.
The F137L mutation of Cx30.3 decreases coupling
and gap junctions of HeLa cells expressing Cx31
Microinjection of Lucifer Yellow revealed limited coupling in
HeLa cells expressing the wild-type form of Cx31 (data not
shown). The incidence and extent of this coupling was
significantly increased between cells coexpressing this con-
nexin together with WT-Cx30.3 (Table 1 and Fig. 4). In
contrast, cells coexpressing WT-Cx31 and F137L-Cx30.3
showed a much decreased (P< 0.001) coupling (Table 1 and
Fig. 4). This difference correlated with different sizes of gap
junction plaques, as evaluated on freeze-fracture replicas of
membranes of transfected HeLa cells. Thus, whereas cells
coexpressing the wild-type form of WT-Cx31 and WT-Cx30.3
featured a sizable number of very large gap junction plaques,
cells expressing WT-Cx31 and F137L-Cx30.3 showed less
abundant and much smaller gap junctions and appeared unable
to concentrate large numbers of connexons into individual
plaques (Table 1 and Fig. 4).
Interaction between both connexins
To test whether Cx31 and Cx30.3 interact, we immunopreci-
pitated a total extract of protein of HeLa cells stably
coexpressing WT-Cx31 and WT-Cx30.3, using antibodies
against the Cx30.3-Myc tag fusion protein. The precipitated
fraction was then analyzed on western blots with antibodies
directed against the Cx31-V5 tag protein (Fig. 5A). Cx31-V5
was detected in the precipitated fraction, indicating a physical
interaction between Cx31 and Cx30.3. This interaction was
also observed in cells coexpressing WT-Cx31 with F137L-
Cx30.3, indicating that the Cx30.3 mutation F137L does not
disturb the oligomerization of both connexins into connexons.
Co-immunoprecipitation was also performed after incubation
of the cells with brefeldin A (BFA), which disrupts the Golgi
apparatus. This interaction can be detected after treatment with
BFA, meaning that this interaction takes place before the
passage through the Golgi apparatus (Fig. 5B).
Turnover of cell surface connexins in Brefeldin A
treated HeLa cells expressing WT-Cx31
and WT-Cx30.3
The observation of very large gap junctional plaques in
presence of both wild-type proteins could be the sign of a slow
degradation of the proteins. Thus, we analyzed cells by
inmmunofluorescence after treatment with BFA to block the
transport of newly synthesized connexins to the cell surface and
to allow us to monitor the disappearance of WT-Cx31/WT-
Cx30.3 gap junction plaques. The intense staining at apposi-
tional membranes in untreated cells was rapidly lost in BFA
(5 mg/mL) treated culture (Fig. 6A–C). The plaques became
smaller and the intracellular staining, corresponding to newly
synthesized connexin (28), increased. After 6 h almost all gap
junctions had been degraded (Fig. 6C), leading to the
conclusion that the time needed to degrade large plaques
formed in presence of both wild-type connexins is normal (29).
The mechanism of disappearance of membrane staining was
inhibited when cells were simultaneously treated with MG132
a proteasome inhibitor (Fig. 6D), indicating that the degrada-
tion of gap junctional plaques is due to the proteasome.
Cx31 and Cx30.3 degradation
We treated cultured cells with either proteasome or lysosome
inhibitors, two pathways implicated in the destruction of
integral membrane proteins (27), to study the degradation of
Cx31 and Cx30.3. Treatment of cells coexpressing Cx31 and
Cx30.3 with MG132 led to an accumulation of connexins at
plasma membrane in presence of WT-Cx30.3 (Fig. 7E) and in
the cytoplasm in presence of F137L-Cx30.3 (Fig. 7F), leading
to the conclusion that the proteasome plays a role in normal
degradation of connexin integrated into gap junction and in
degradation of mutant protein at the exit of the endoplasmic
reticulum (ER). The effect is confirmed by a cotreatment of
cells coexpressing WT-Cx31 and WT-Cx30.3 with BrefeldinA
and MG132, indicating the implication of the proteasome in
the degradation of gap junctional plaques but not in
degradation of newly synthesized connexins (Fig. 6D).
Treatment with chloroquine did not change the staining of
cells coexpressing WT-Cx31 and WT-Cx30.3 (Fig. 7C). On the
Table 1. The F137L mutation of Cx30.3 decreases gap junctions and coupling in HeLa cells expressing WT-Cx31
Cell line Dye coupling Electron microscopy
No. of cells
injected
No. (%) of cells exchanging
Lucifer Yellowa
No. of cells scored
(% with gap junctions)
No. (%) of cells showing
gap junctionsa
0 2–3 >3 Minute Medium Large
WT-Cx31/WT-Cx30.3 20 1 (5) 2 (10) 17 (85) 110 (38) 12 (21) 24 (41) 22 (38)
WT-Cx31/F137L-Cx30.3 17 5 (29) 10 (59) 2 (12) 109 (29) 36 (60) 21 (34) 4 (6)
aP> 0.001 WT-Cx31/F137L-Cx30.3 versus WT-Cx31/WT-Cx30.3, as compared by a w2 test.
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contrary, the cytoplasmic staining was more intense than in the
control when WT-Cx31 and F137L-Cx30.3 were coexpressed
(Fig. 7D). Chloroquine blocks a lysosomal pathway of
degradation which occurs at the exit of the ER for protein
misfolded or with a problem in oligomerization. We can also
note that, even when the degradation of F137L-Cx30.3 is
blocked, connexins are not exported to the plasma membrane
(Fig. 7D), indicating that the mutation leads to the degradation
of the protein at the exit of the ER.
DISCUSSION
The formation of functional gap junctions results in a series of
intracellular processes that assemble connexin subunits into
connexon hemichannels before their delivery to the plasma
membrane (30). Connexins are maturated in the ER where they
are then oligomerized into connexons (31). Connexons are then
exported via the Golgi apparatus to the membrane of the cells.
During gap junction formation, connexons align and dock with
partners in neighboring plasma membranes to generate gap
junction intercellular channels. Mutations in connexin may
modify or disrupt those events that lead to channel formation and
operation. Two genes of the same family of proteins cause the
two distinct forms of erythrokeratodermia variabilis and these
two genes are expressed during the process of epidermal
differentiation. These two facts led us to hypothesize that Cx31
and Cx30.3 could interact structurally or functionally at the
molecular level and that this interaction is important for
epidermal homeostasis. The high majority of mutations of
Cx31 and Cx30.3 concern the transmembrane domains of the
proteins, i.e. the most conserved parts of connexins. The F137L
mutation in Cx30.3 affects a highly conserved amino acid of the
third transmembrane domain. By analogy to Cx32, we know that
this amino acid faces the lumen of the gap junction channel (23).
In this study, we have used stable mammalian cell lines
in order to obtain reproducible conditions to analyze the
interaction of WT-Cx31 and WT-Cx30.3 as well as the F137L-
Cx30.3 mutation associated with EKV. We decided to use HeLa
cells for expressing our connexins as they are deficient in
connexins and do not form gap junctions. Thus we observed
the interaction of both connexins without the intervention of
Figure 3. Immunofluorescence analysis of HeLa cells stably expressing
WT-Cx31 and WT-Cx30.3 (A, C, E) or WT-Cx31 and F137L-Cx30.3 (B, D,
F) with anti-V5 antibody (Cx31) in (A, C, E) or anti-myc antibody (Cx30.3)
in (B, D, F). The superposed images are shown in (E) and (F). (G) The
TritonX-100 insoluble form of Cx31 is markedly decreased in presence of
F137L-Cx30.3. Cx31 was detected with an anti-V5 antibody in insoluble (P)
or soluble (S) fractions.
Figure 4. The F137L mutation of Cx30.3 decreases coupling and gap junctions
of HeLa cells expressing WT-Cx31. After a 5min injection, most HeLa cells
co-expressing the wild-type forms of Cx31 and Cx30.3 exchanged Lucifer
Yellow with several of their neighbors (A). Lucifer Yellow transfer was
markedly decreased between HeLa cells co-expressing the wild-type form of
Cx31 and the F137L mutation of Cx30.3 (B). Freeze-fracture analysis of the
plasma membrane of cells expressing both WT connexins revealed that most
of these cells were joined by large gap junction plaques (C). When WT-Cx31
and F137L-Cx30.3 were coexpressed, freeze-fracture analysis showed that most
of these cells were linked by minute gap junctions (D).
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other connexins, that is to say in a model different from
the natural situation, but allowing the study of a precise
interaction. In contrast, skin is rather complex for the study of
connexin as keratinocytes express a large panel of connexins
and Cx31 and Cx30.3 are not predominant. Cx30.3 is
expressed in various tissues (skin, kidney, placenta) (9), but
the F137L mutation leads only to EKV, indicating that the
effect of this connexin mutation may be cell-specific.
Nevertheless, since mutations of connexins weakly expressed
in the epidermis lead to disease, this indicates that their function
is of major importance. Intercellular communication mediated
by both Cx31 and Cx30.3 affects epidermal differentiation
significantly.
Our results indicate that Cx31 and Cx30.3 oligomerize to
form heteromeric connexons. First, simultaneous immunostain-
ing experiments showed that both connexins colocalized to the
same junctional plaques at interfaces between cells. Secondly,
the formation of plaques is greatly enhanced in the presence of
both wild-type connexins compared to the single connexin
expression, and this is not due to a slow degradation as the
turnover of the protein is classical. Furthermore, this coopera-
tion of both connexins occurs during the oligomerization of
heteromeric connexons and not during the formation of
heterotypic channels. The expression of WT-Cx30.3 in a cell
neighboring a cell expressing WT-Cx31 does not lead to the
formation of large plaques. It seems that Cx30.3 needs to
heteromerize with another connexin to be efficiently exported
to the plasma membrane as very small dots were observed
when it was expressed alone. Since only Cx31 and Cx30.3 have
so far been implicated in EKV, we did not look for their
interaction with other connexins also expressed in the skin,
such as Cx26, Cx30 or Cx43. Cx30.3 could interact with some
of these connexins. Similar to our present observations, Cx26
and Cx30 have been described to interact and Cx26 mutations
to have a dominant negative effect on Cx30 (32). However, the
reported coexpression of Cx26 and Cx30 did not enhance the
formation of gap junction at cell membrane (32). To our
knowledge, this is the first report providing experimental
evidence for molecular interaction of connexins with hetero-
dimeric stabilization. Furthermore, this molecular interaction
provides a novel explanation for the similarity of EKV
phenotypes Mendes da Costa (Cx31) and EKV Cram–
Mevorah (Cx30.3).
Mutations of connexins can disturb different stages in their life
cycle (9). The F137L mutation does not lead to a premature stop
codon and does not interfere with protein oligomerization as we
have been able to coprecipitate Cx30.3 and Cx31 even in the
presence of the mutation. In presence of the F137L mutation of
Cx30.3, very few gap junctions are formed (TritonX-100
solubility and electron microscopy) and consequently only a few
dots were observed at the membrane by immunofluorescence,
and the coupling between adjacent cells was sharply decreased
compared with the cell coexpressing both wild-type connexins.
As our protein was not detected at plasma membrane, a
disturbance of connexon docking or an alteration of gap
junction permeability was excluded. The stage disturbed by our
mutation is the protein folding, leading to the degradation of the
protein at the exit of the endoplasmic reticulum. This kind of
trafficking defect was already observed with mutant connexin31
(5,33) or connexin32 (34), for example. There is a selective
recognition, retention and degradation of incorrectly folded
proteins known as quality control process (27). Mutations of
Cx31, including F137L-Cx31 (35), have also been described to
lead to cell death (5,36). In contrast, F137L-Cx30.3 did not lead
to this phenomenon in either our HeLa cells nor in HaCat cells
(35), consistent with the lack of obvious cell death in EKV.
Figure 5. Cx31 and Cx30.3 interact before entering Golgi apparatus. (A) Total
extract of HeLa cells expressing WT-Cx31 (lane 1), WT-Cx31/WT-Cx30.3
(lane 2), WT-Cx31/F137L-Cx30.3 (lane 3) and WT-Cx30.3 (lane 4) were pre-
cipited with an anti-myc antibody and detected on western blot with an anti-
V5 antibody. (B) HeLa cells expressing WT-Cx31/WT-Cx30.3 (lanes 1
and 12) and WT-Cx31/F137L-Cx30.3 (lanes 3 and 4) were immunoprecipitated
as described above (lanes 1 and 3) or immunoprecipitated after treatment with
BFA for 6 h (lanes 2 and 4).
Figure 6. Immunofluorescent detection of the loss of cell surface WT-Cx31 in
BrefeldinA treated WT-Cx31/WT-Cx30.3 cells and inhibition of this mechanism
by a proteasome inhibitor. Cells were treated with Brefeldin A for the indicated
times (A, B, C) or with BFA and MG132 (D) prior to immunofluorescence
analysis with anti-V5 antibody (in red).
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In summary, Cx30.3 mutation F137L prevents the trafficking
of Cx31 and itself to the membrane of the cells and leads to a
decrease in cellular coupling. Thus communication of epider-
mal cells is sharply disturbed in presence of this mutation. Our
study is the first clue indicating an interaction between Cx31
and Cx30.3 in the formation of gap junctions.
MATERIALS AND METHODS
Cell culture
HeLa and 293T cells were grown in Dulbecco’s modified
Eagle’s medium (Gibco) containing 10% fetal calf serum,
100U/ml Penicillin and 0.1mg/mL Streptomycin. Zeocin
(Invitrogen) was added at a concentration of 600 mg/ml for
selection of stably transfected cells. Cells were grown on cover
slips for immunostaining.
Cells were incubated with 5 mg/ml BrefeldinA (Sigma) for 1,
3 and 6 h. They were also incubated for 3 h with different
protease inhibitors: 40 mM MG132 (Calbiochem) and 200 mM
Chloroquine (Fluka BioChemica).
Antibodies
The following antibodies were used: rabbit anti c-myc antibody
(1 : 3000; Santa Cruz Biotechnology Inc.); mouse anti V5
antibody (1 : 5000; Invitrogen); anti-Rabbit IgG, HRP-linked
antibody (1 : 3000; Amersham Bioscience); anti-mouse IgG,
HRP-linked antibody (1 : 5000; Amersham Bioscience); rabbit
immunoglobulins-FITC (1 : 40; DAKO); biotinylated anti-mouse
IgG antibody (1 : 100; Vector, Switzerland); Streptavidin–Texas
Red (1 : 400; Amersham Life Science); Alexa488 goat anti rabbit
(1 : 200; A11070 Juro Supply).
Construction of chimeric Cx31-V5 and Cx30.3-Myc
The coding sequence of wild-type Cx31 and Cx30.3 and that of
F137L-Cx30.3 were amplified with specific primers containing
restriction site sequences. Cx31 was cloned in SfuI sites of
pBudCE4 plasmid (Invitrogen) with primers TTCGAAGGCG
CCATGGACTGGAAGACA (forward) and TTCGAAGATGG
GGGTCAGGTTGGGTGC (reverse). Cx30.3 was cloned using
a forward primer containing a HindIII site (AAGCTTGCACC
ATGAACTGGGCATTT) and a reverse primer containing
an XbaI site (TCTAGATGGATACCCACCTGCATCCAC).
Cloning was designed so that the inserts were fused with
C-terminal tags. Constructions were assessed by sequencing
and enzymatic digestion.
Transfection and selection
HeLa cells were transfected with lipofectamine (Invitrogen)
or lipofectamine2000 (Invitrogen). After 48 h, medium was
replaced by the selection medium containing Zeocin
(Invitrogen). Single colonies were isolated and grown sepa-
rately to expand monoclonal cell lines.
Extraction of proteins and immunoblotting
Cells were harvested in lysis buffer containing 10mM Tris–HCl
(pH 7.5), 5mM EDTA, 50 mg/ml PMSF and complete anti-
protease mixture (Roche).
Protein extracts were heated for 5min at 95C. After
separation on SDS polyacrylamide gels, proteins were trans-
ferred onto nitrocellulose membrane, stained with Ponceau and
then incubated with antibodies.
For TritonX-100 solubility assay, cells were harvested in a
buffer containing 1% Triton-X100, 145mM NaCl, 10mM Tris–
HCl pH 7.4, 5mM EDTA, 2mM EGTA and 1mM PMSF. After
30min centrifugation, soluble and insoluble fractions were
separated by western blotting.
Co-immunoprecipitation
Cells were harvested by scraping in a buffer containing PBS,
1% Triton X-100, 0.5% CHAPS, 0.1% SDS, and protease
inhibitors (37) (IP buffer). The myc antibody was used to
precipitate Cx30.3. The antigen–antibody complexes were
collected using protein G-Sepharose beads, washed first with IP
buffer without protease inhibitors supplemented with 0.5 M
Sucrose and 0.5% BSA and then with IP buffer and analyzed
by SDS–PAGE, using an anti-V5 antibody.
Figure 7. Influence of inhibitors of proteasome and lysosome on the degrada-
tion of connexins in cells coexpressing WT-Cx31 with either WT-Cx30.3 (A, C
and E) or F137L-Cx30.3 (B, D and F). Cells were cultured without protease
inhibitor (A, B) or treated with chloroquine (C, D) or MG132 (E, F) prior to
immunolabelling with anti-V5 antibody.
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Immunofluorescence
Cells were grown on cover slips and fixed in methanol acetone
(1 : 1). After blocking in 1% BSA–PBS (1 h at 37C), cells
were incubated for 2 h at 37C with primary antibodies and
then exposed to secondary and ternary antibodies if necessary
(30min each). Cover slips were mounted in fluorescent
mounting medium (DAKO Diagnostic AG). Images were
acquired using a Zeiss Axioskop microscope (Carl Zeiss,
Germany) and processed with an RT color SPOT CCD Camera
(Diagnosis Instruments Inc.) and Adobe Photoshop 6. Green
and red fluorescence were collected separately. There was no
signal from the green channel in the red one and vice versa.
Dye coupling
For assessment of junctional coupling, individual cells were
microinjected by iontophoresis within monolayer cultures,
using microelectrodes containing 4% Lucifer Yellow CH
(Sigma Chemical Co., St Louis, MO, USA) in 150mM LiCl.
The percentage of microinjected cells that exhibited cell-to-
cell transfer of Lucifer Yellow was determined on photographs
taken immediately after each microinjection.
Electron microscopy
For assessment of gap junction plaques, cells were fixed for
60min in a 2.5% glutaraldehyde solution in 0.1 M phosphate
buffer, infiltrated with 30% glycerol, frozen in Freon22 cooled
in liquid nitrogen, and processed for freeze-fracture using a
Balzers BAF (Balzers High Vacuum, Balzers, Liechtenstein).
Replicas were examined in a Philips EM 300 microscope.
ACKNOWLEDGEMENTS
We thank Caroline Lehmann for technical assistance and
Fabrice Chimienti and Bertrand Favre for helpful discussion.
The work of the Hohl team is supported by grants from the
Swiss National Science Foundation and Telethon. The work of
the Meda team is supported by grants from the Swiss National
Foundation (3100-067788.02), the Fondation Romande pour la
Recherche sur le Diabe`te, the Juvenile Diabetes Research
Foundation International (1-2001-622), the European Union
(QLRT-2001-01777) and the National Institutes of Health
(DK 63443-01).
REFERENCES
1. Willecke, K., Eiberger, J., Degen, J., Eckardt, D., Romualdi, A.,
Guldenagel, M., Deutsch, U. and Sohl, G. (2002) Structural and
functional diversity of connexin genes in the mouse and human genome.
Biol. Chem., 383, 725–737.
2. Goodenough, D.A. and Paul, D.L. (2003) Beyond the gap: functions
of unpaired connexon channels. Nat. Rev. Mol. Cell. Biol., 4, 285–294.
3. Richard, G. (2000) Connexins: a connection with the skin.
Exp. Dermatol., 9, 77–96.
4. Krutovskikh, V. and Yamasaki, H. (2000) Connexin gene mutations in
human genetic diseases. Mutat. Res., 462, 197–207.
5. Di, W.L., Monypenny, J., Common, J.E., Kennedy, C.T., Holland, K.A.,
Leigh, I.M., Rugg, E.L., Zicha, D. and Kelsell, D.P. (2002) Defective
trafficking and cell death is characteristic of skin disease-associated
connexin 31 mutations. Hum. Mol. Genet., 11, 2005–2014.
6. Hennemann, H., Dahl, E., White, J.B., Schwarz, H.J., Lalley, P.A.,
Chang, S., Nicholson, B.J. and Willecke, K. (1992) Two gap junction genes,
connexin 31.1 and 30.3, are closely linked on mouse chromosome 4 and
preferentially expressed in skin. J. Biol. Chem., 267, 17225–17233.
7. Di, W.L., Rugg, E.L., Leigh, I.M. and Kelsell, D.P. (2001) Multiple
epidermal connexins are expressed in different keratinocyte subpopulations
including connexin 31. J. Invest. Dermatol., 117, 958–964.
8. Richard, G., Brown, N., Rouan, F., Van der Schroeff, J.G., Bijlsma, E.,
Eichenfield, L.F., Sybert, V.P., Greer, K.E., Hogan, P., Campanelli, C. et al.
(2003) Genetic heterogeneity in erythrokeratodermia variabilis: novel
mutations in the connexin gene GJB4 (Cx30.3) and genotype-
phenotype correlations. J. Invest. Dermatol., 120, 601–609.
9. Richard, G. (2003) Connexin gene pathology. Clin. Exp. Dermatol., 28,
397–409.
10. Kelsell, D.P., Di, W.L. and Houseman, M.J. (2001) Connexin mutations
in skin disease and hearing loss. Am. J. Hum. Genet., 68, 559–568.
11. Kelsell, D.P., Wilgoss, A.L., Richard, G., Stevens, H.P., Munro, C.S. and
Leigh, I.M. (2000) Connexin mutations associated with palmoplantar
keratoderma and profound deafness in a single family. Eur. J. Hum.
Genet., 8, 469–472.
12. Richard, G., Rouan, F., Willoughby, C.E., Brown, N., Chung, P.,
Ryynanen, M., Jabs, E.W., Bale, S.J., DiGiovanna, J.J., Uitto, J. et al. (2002)
Missense mutations in GJB2 encoding connexin-26 cause the
ectodermal dysplasia keratitis–ichthyosis–deafness syndrome. Am. J. Hum.
Genet., 70, 1341–1348.
13. van Steensel, M.A., van Geel, M., Nahuys, M., Smitt, J.H. and
Steijlen, P.M. (2002) A novel connexin 26 mutation in a patient
diagnosed with keratitis-ichthyosis-deafness syndrome. J. Invest.
Dermatol., 118, 724–727.
14. Lamartine, J., Munhoz Essenfelder, G., Kibar, Z., Lanneluc, I., Callouet, E.,
Laoudj, D., Lemaitre, G., Hand, C., Hayflick, S.J., Zonana, J. et al. (2000)
Mutations in GJB6 cause hidrotic ectodermal dysplasia. Nat. Genet.,
26, 142–144.
15. Richard, G., Smith, L.E., Bailey, R.A., Itin, P., Hohl, D., Epstein, E.H., Jr.,
DiGiovanna, J.J., Compton, J.G. and Bale, S.J. (1998) Mutations in the
human connexin gene GJB3 cause erythrokeratodermia variabilis. Nat.
Genet., 20, 366–369.
16. Wilgoss, A., Leigh, I.M., Barnes, M.R., Dopping-Hepenstal, P., Eady, R.A.,
Walter, J.M., Kennedy, C.T. and Kelsell, D.P. (1999) Identification of a
novel mutation R42P in the gap junction protein beta-3 associated with
autosomal dominant erythrokeratoderma variabilis. J. Invest. Dermatol.,
113, 1119–1122.
17. Liu, X.Z., Xia, X.J., Xu, L.R., Pandya, A., Liang, C.Y., Blanton, S.H.,
Brown, S.D., Steel, K.P. and Nance, W.E. (2000) Mutations in connexin31
underlie recessive as well as dominant non-syndromic hearing loss.
Hum. Mol. Genet., 9, 63–67.
18. Richard, G., Brown, N., Smith, L.E., Terrinoni, A., Melino, G.,
Mackie, R.M., Bale, S.J. and Uitto, J. (2000) The spectrum of mutations in
erythrokeratodermias—novel and de novo mutations in GJB3. Hum.
Genet., 106, 321–329.
19. Xia, J.H., Liu, C.Y., Tang, B.S., Pan, Q., Huang, L., Dai, H.P., Zhang, B.R.,
Xie, W., Hu, D.X., Zheng, D. et al. (1998) Mutations in the gene
encoding gap junction protein beta-3 associated with autosomal dominant
hearing impairment. Nat. Genet., 20, 370–373.
20. Gottfried, I., Landau, M., Glaser, F., Di, W.L., Ophir, J., Mevorah, B.,
Ben-Tal, N., Kelsell, D.P. and Avraham, K.B. (2002) A mutation in
GJB3 is associated with recessive erythrokeratodermia variabilis (EKV)
and leads to defective trafficking of the connexin 31 protein. Hum. Mol.
Genet., 11, 1311–1316.
21. Macari, F., Landau, M., Cousin, P., Mevorah, B., Brenner, S., Panizzon, R.,
Schorderet, D.F., Hohl, D. and Huber, M. (2000) Mutation in the gene
for connexin 30.3 in a family with erythrokeratodermia variabilis. Am.
J. Hum. Genet., 67, 1296–1301.
22. Lopez-Bigas, N., Melchionda, S., Gasparini, P., Borragan, A.,
Arbones, M.L. and Estivill, X. (2002) A common frameshift mutation
and other variants in GJB4 (connexin 30.3): Analysis of hearing
impairment families. Hum. Mutat., 19, 458.
23. Skerrett, I.M., Aronowitz, J., Shin, J.H., Cymes, G., Kasperek, E., Cao, F.L.
and Nicholson, B.J. (2002) Identification of amino acid residues lining the
pore of a gap junction channel. J. Cell. Biol., 159, 349–360.
24. Musil, L.S. and Goodenough, D.A. (1991) Biochemical analysis of
connexin43 intracellular transport, phosphorylation, and assembly into gap
junctional plaques. J. Cell. Biol., 115, 1357–1374.
Human Molecular Genetics, 2003, Vol. 12, No. 24 3293
25. Musil, L.S. and Goodenough, D.A. (1993) Multisubunit assembly of an
integral plasma membrane channel protein, gap junction connexin43,
occurs after exit from the ER. Cell, 74, 1065–1077.
26. Larson, D.M., Seul, K.H., Berthoud, V.M., Lau, A.F., Sagar, G.D. and
Beyer, E.C. (2000) Functional expression and biochemical characterization
of an epitope-tagged connexin37. Mol. Cell. Biol. Res. Commun., 3,
115–121.
27. VanSlyke, J.K., Deschenes, S.M. and Musil, L.S. (2000) Intracellular
transport, assembly, and degradation of wild-type and disease-linked
mutant gap junction proteins. Mol. Biol. Cell., 11, 1933–1946.
28. Laing, J.G., Tadros, P.N., Westphale, E.M. and Beyer, E.C. (1997)
Degradation of connexin43 gap junctions involves both the proteasome
and the lysosome. Exp. Cell. Res., 236, 482–492.
29. Musil, L.S., Le, A.C., VanSlyke, J.K. and Roberts, L.M. (2000) Regulation
of connexin degradation as a mechanism to increase gap junction assembly
and function. J. Biol. Chem., 275, 25207–25215.
30. Martin, P.E., Mambetisaeva, E.T., Archer, D.A., George, C.H. and
Evans, W.H. (2000) Analysis of gap junction assembly using mutated
connexins detected in Charcot–Marie–Tooth X-linked disease.
J. Neurochem., 74, 711–720.
31. Falk, M.M. (2000) Biosynthesis and structural composition of gap junction
intercellular membrane channels. Eur. J. Cell. Biol., 79, 564–574.
32. Marziano, N.K., Casalotti, S.O., Portelli, A.E., Becker, D.L. and Forge, A.
(2003) Mutations in the gene for connexin 26 (GJB2) that cause
hearing loss have a dominant negative effect on connexin 30. Hum. Mol.
Genet., 12, 805–812.
33. Rouan, F., Lo, C.W., Fertala, A., Wahl, M., Jost, M., Rodeck, U., Uitto, J.
and Richard, G. (2003) Divergent effects of two sequence variants of
GJB3 (G12D and R32W) on the function of connexin 31 in vitro.
Exp. Dermatol., 12, 191–197.
34. Deschenes, S.M., Walcott, J.L., Wexler, T.L., Scherer, S.S. and
Fischbeck, K.H. (1997) Altered trafficking of mutant connexin32.
J. Neurosci., 17, 9077–9084.
35. Rouan, F., Yi, L., Uitto, J. and Richard, G. (2003) Pathogenic
mutations affecting Cx31 and Cx30.3 impair gap junction function and
induce cell death. IID 2003. J. Invest. Dermatol., Miami, Fl, Vol. 121, p. 602.
36. Diestel, S., Richard, G., Doring, B. and Traub, O. (2002) Expression
of a connexin31 mutation causing erythrokeratodermia variabilis
is lethal for HeLa cells. Biochem. Biophys. Res. Commun., 296,
721–728.
37. Laing, J.G., Manley-Markowski, R.N., Koval, M., Civitelli, R. and
Steinberg, T.H. (2001) Connexin45 interacts with zonula occludens-1
and connexin43 in osteoblastic cells. J. Biol. Chem., 276,
23051–23055.
3294 Human Molecular Genetics, 2003, Vol. 12, No. 24
